Beauty Health (SKIN) & The Competition Financial Survey

Beauty Health (NASDAQ:SKINGet Rating) is one of 213 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its competitors? We will compare Beauty Health to similar businesses based on the strength of its risk, profitability, institutional ownership, analyst recommendations, earnings, dividends and valuation.


This table compares Beauty Health and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Beauty Health -117.84% -0.01% N/A
Beauty Health Competitors -678.57% -64.71% -19.37%

Volatility and Risk

Beauty Health has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500. Comparatively, Beauty Health’s competitors have a beta of 1.13, suggesting that their average stock price is 13% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Beauty Health and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beauty Health 0 1 9 0 2.90
Beauty Health Competitors 1266 4582 7983 221 2.51

Beauty Health presently has a consensus price target of $26.11, suggesting a potential upside of 111.25%. As a group, “Surgical & medical instruments” companies have a potential upside of 55.97%. Given Beauty Health’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Beauty Health is more favorable than its competitors.

Institutional & Insider Ownership

72.0% of Beauty Health shares are owned by institutional investors. Comparatively, 50.7% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 14.1% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Beauty Health and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Beauty Health $260.09 million -$375.11 million -3.64
Beauty Health Competitors $1.15 billion $84.54 million -477.59

Beauty Health’s competitors have higher revenue and earnings than Beauty Health. Beauty Health is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


Beauty Health beats its competitors on 8 of the 12 factors compared.

About Beauty Health (Get Rating)

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company’s flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer’s preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.

Receive News & Ratings for Beauty Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Beauty Health and related companies with’s FREE daily email newsletter.

Beauty Health (SKIN) & The Competition Financial Survey

Next Post

Hope for acne sufferers as dermatologists identify possible link between key nutrient and skin condition

Credit: Pixabay/CC0 Public Domain Dermatologists in Germany have identified what could be a crucial link between acne and a deficit of omega-3 fatty acids. The findings, released during the European Academy of Dermatology and Venereology (EADV) Spring Symposium, could offer new opportunities for managing a condition estimated to affect nearly […]